We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas.


 Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3.  Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs.  The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively.


 The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.
MENs
We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas.


 Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3.  Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs.  The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively.


 The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.
MENs
We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas.


 Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3.  Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs.  The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively.


 The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.
MENs
We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas.


 Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3.  Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs.  The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively.


 The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.
MENs